1. Sino Biopharm 2025 Annual Innovative Drug Development Progress
Sino Biopharm in2025Year Total18 Payment1 New class of drugs approved for clinical trials for the first time, covering oncology, metabolism,Surgery/Analgesia, respiration, and other fields, includingADC、PROTAC, bispecific antibodies and other cutting-edge technologies. ItsIn China,ADCDrugTQB6411（EGFR/c-MetBispecific AntibodyADC）、TQB2101（ROR1ADC）AndLM-350（CDH17 ADC) Constructed a multi-target innovation matrix;PROTACDrugTQB3019（BTKDegradant),TQB3142（Bcl-xLDegradant) andTQB3201（ARDegradation agent) cracked"Not possiblePatent Medicine"Challenge. The company has enhanced the convenience of medication through the innovation of subcutaneous injection formulations, and is simultaneously advancing in the United States andThe global clinical development in Australia and other regions reflects its innovation-driven and internationalization strategy.
2. Zongai Tinib Treatment HER2 Breakthrough in Mutant Non-Small Cell Lung Cancer
In 2025 Year ESMO At the Asian Conference ，Beamion LUNG-1 Study Announces Zong Aitinib（Zongertinib) Treatment HER2 SuddenNon-small cell lung cancer (NSCLC) Data from Asian patients confirmedIts remarkable efficacy. Professor Wenfeng Fang from the Sun Yat-sen University Cancer Center pointed out,Zong Ai替尼 as a novel HER2Targeted drugs have addressed the clinical pain points of high drug resistance and limited efficacy in previous treatments. This drug has been approved. NCCNAndCSCO The guidelines recommend that the data from Asian populations further validate the consistency of efficacy across races, providingHER2Mutation NSCLC Provides a new paradigm for precision treatment and is expected to lead the exploration of future combination therapy regimens.
3. Professor Ma Jun Promotes Lymphoma AI Doctor Standard Formulation
Professor Jun Ma, Director of Harbin Hematology and Oncology Research Institute, took the lead in formulatingLymphoma Diagnosis AI Doctor's Standard, EmphasizingAI The auxiliary role needs to be clarified to ensure medical safety. The standard system covers functional boundary definition and technical specifications.Scope, Audit Mechanism, and Risk Management: Requirements AI The system has a high diagnostic accuracy rate andInterpretability. Professor Ma JunTaught through clinical cases (e.g., AI (Aided Discovery of Rare Causes) ShowcasedAI In the diagnosis of difficult and complicated diseases, resource optimizationThe Value in Transformation and Patient Follow-up. He called for the establishment of an inclusive AI Medical products, promoting technology to benefit grassroots levels,And strengthen the combination of medical and engineering as well as talent cultivation to build a trustworthy AI Medical Treatment Ecosystem.
4. MindRank AI Design GLP-1 Drug EntryEntry III Phase Clinical
On December 22, MindRank announced that its AI Designed Small MoleculesGLP-1Receptor AgonistMDR-001 LaunchIII PendingClinical trials, marking the first in ChinaAI MindRank's AI-aided drug enters confirmatory clinical stage.MDR-001 InIIbShowed excellent safety (no serious adverse events) and efficacy (24 Weekly Weight Loss10.3%），Its cardiovascular metabolic indicators improved significantly, and it demonstrated a marked advantage in reducing transaminase levels. The drug advanced in just four and a half years toIIIPeriod,HighlightAIPharmaceutical PlatformMoleculeProThe efficiency, for China in oral small moleculeGLP-1Field Impact“Best-in-class"Provides a milestone case.
5. Kelun Biotech's Lecanemab to be Included in Breakthrough Therapy
On December 25, the lutikizumab (SKB264) Combined with PaBolizumab First-Line TreatmentPD-L1Positive Non-Small Cell Lung Cancer (NSCLC) Proposed for inclusion in the breakthrough therapy, this is its6 Breakthrough Therapy DesignationSet.IIIPeriodOptiTROP-Lung05 ResearchReached the primary endpoint of progression-free survival, with overall survival showing a beneficial trend, becoming the world's firstIO+ADC On the FrontlineNSCLCPositive results obtained in ChinaIIIPhase Research.The drug has been previouslyEGFRMutationNSCLCAchievement in Later-line TreatmentPFS AndOS DoubleRegain benefits, this timeMove forward to further consolidate its best-in-class potential in the field of lung cancer.
6. Innovent Biologics' Dual Immunotherapy Approved for Neoadjuvant Indication in Colon Cancer
December 25, Innovent Biologics' Tyvyt®(IpilimumabN01 Injection) combined with Da Bo Shu®(TrustDilizumab InjectionInjection) ObtainedNMPA Approval for surgically resectableIIB-IIIPeriodMSI-H/dMMRNeoadjuvant Therapy for Colon CancerTreatment, becoming the world's first and only dual immunotherapy regimen approved for this indication.IIIPeriodNeoShot-IIIResearch showsShow DiseasePrincipleCompleteAlleviateRate Achievement82% ，SignificantAuthorDecreaseLowArtAfterChemotherapyNegativeUndertake。The therapyLawFillReplenishedMSI-H/dMMR Filling the Gap in Neoadjuvant Therapy for Colon Cancer and ThroughCTLA-4AndPD-1 Dual-target Synergistic MechanismImproved efficacy, providing Chinese patients with a new curative treatment option.
7. Zhejiang University Sir Run Run Shaw Hospital Liver Cancer AI MindRank Ranks First in National Evaluation
Multimodal Liver Cancer Developed by Sir Run Run Shaw Hospital of Zhejiang University AI Large Model Agents in National Artificial Intelligence ApplicationsTest Base Evaluation"Intelligent Auxiliary Diagnosis "First in the Special Project. The model is based on a tens of millions medical knowledge graph andMultimodal Fusion Technology for Achieving Emergency Recognition Response Time 8.3 Seconds, Diagnostic Accuracy 84.5% RunDa HealthcareAs a partner to promote its clinical transformation, the achievement has been successfully converted into results. 2400 Ten thousand yuan, and countingRowing to Kunshan and other grassroots areas
Promotion of the Medical System. This intelligent agent embodies“ Clinically Driven+Data Empowerment " AI Medical Convergence Pathway,Provides an intelligent solution for the whole-process management of liver cancer.
8. Junshi Biosciences EGFR/HER3 Bispecific Antibody ADC Enter II Phase Clinical
Junshi Biosciences EGFR/HER3 Bispecific Antibody ADC Drug JS212 Launch II Phase clinical, becoming the second globallyThe first product of its kind to enter this phase. The study will evaluate JS212 United PD-1 Antibody TeriparatideLidunan, PD-1/VEGF Bispecific Antibody JS207 Or PD-1/IL-2 Bispecific Antibody JS213 Efficacy in advanced lung cancer, planned enrollment846 Example patient.JS212 Overcome through dual-target synergy EGFR Drug Resistance Mechanism: Preclinical Studies ShowSignificant tumor inhibition activity. Junshi Biosciences, relying on multi-technology platform collaborative development, is expected to enhance its potential through combination strategies.Competitiveness in the field of lung cancer.
9. Enrui Kainuo CAR-NK Therapy Selected as One of the Top Ten Clinical Breakthroughs Worldwide
Enruikainuo's Universal Type CD19 CAR-NK Therapy KN5501 Due to the treatment of systemic lupus erythematosusLupus（SLE) The breakthrough results were selected 2025 Year"Top Ten GlobalBed Breakthrough ". Published in The Lancet"Research shows,18 Refractory Case SLE After the patient received treatment,6 Complete clinical remission rate reached in months 55.6%，And no serious adverse events. The therapy works by"Spot-type "Design to reduce costs to CAR-T One-tenth of,Achieved immune system reset and precise targeting, opening a new path for the treatment of autoimmune diseases, and received national recognition.Highly praised by international authoritative journals.
10. China Clinical Trials Development Report of the Past Decade
2015-2024 In ... year, the number of clinical trials in mainland China increased. 366% ，2024 New Trial in YearTested Globally44%, becoming a new global center for innovative drug research and development. In trials led by Chinese pharmaceutical companies, the proportion in the oncology field exceeds 50%，Overseas trials are preferably conducted in the United States and Australia. Clinical trial efficiency in China has a significant advantage (e.g., shorter patient recruitment cycles).Short 342 Day），But need to start from"Scale Support "Value-Driven" "Transformation. In the future, it is necessary to enhance the allocation of regional resources.Placement, Strengthening International Rule Synergy, and High-Quality Data Publication (16 A Study Reaches the Top Four Journals)Enhance global influence.
The reference materials are from publicly available online information, including news reports, corporate official websites, and government documents.
